CVA Family Office’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-4,264
Closed -$187K 968
2021
Q4
$187K Buy
+4,264
New +$202K 0.05% 172
2021
Q3
Sell
-4,264
Closed -$222K 591
2021
Q2
$222K Buy
+4,264
New +$200K 0.06% 150

Other funds holding IDNA

CVA Family Office's IDNA Position: Q1 2022 in Review

CVA Family Office sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2022, closing a stake of 4,264 shares — an estimated $187K sold.

CVA Family Office first reported a position in IDNA in Q2 2021 and held it in 2 quarters. The position peaked at $222K in Q2 2021. 86 funds tracked by Wall St. Rank hold IDNA as of Q1 2022.

  • CVA Family Office reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2022 after selling out during the quarter.
  • CVA Family Office sold 4,264 iShares Genomics Immunology and Healthcare ETF shares in Q1 2022, an estimated $187K.
  • CVA Family Office first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2021 and held it in 2 quarters.
  • CVA Family Office's iShares Genomics Immunology and Healthcare ETF position peaked at $222K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2022.

Based on CVA Family Office's 13F filing for Q1 2022, filed 22 Apr 2022.